Brian Korb - Investor Relations Karen Zaderej - President and Chief Executive Officer Pete Mariani - Chief Financial Officer.

Dave Turkaly - JMP Securities Tao Levy - Wedbush Securities Bruce Jackson - Lake Street Capital Markets.

Greetings and welcome to the AxoGen’s Fourth Quarter and 2016 Full Year Financial Results Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference will be recorded.

I would now like to turn the conference over to your host, Mr. Brian Korb. Thank you, Mr. Korb. You may begin..

Thank you, operator, and good afternoon, everyone. Thank you for joining us today for the AxoGen conference call to discuss the financial results for the fourth quarter and full year ended December 31, 2016. Today’s call is being broadcast live via webcast, which is available on the AxoGen website.

Within an hour following the end of the live call, a replay will be available on the company’s website at www.axogeninc.com, under Investors. Before we get started, I would like to remind you that during the course of this conference call, the company will make projections and forward-looking statements regarding future events.

We encourage you to review the company’s past and future filings with the SEC, including without limitation, the company’s Forms 10-K and 10-Q which identify the specific factors that may cause actual results or events to differ materially from those described in these forward-looking statements.

These factors may include, without limitation, statements regarding product acquisition and/or development, product potential, regulatory environment, sales and marketing strategies, capital resources and operating performance. And with that, I would like to turn the call over to Karen Zaderej, President and Chief Executive Officer of AxoGen.

Karen?.

build market awareness, educating surgeons and developing advocates; growing the body of clinical evidence; executing on our sales plans; and introducing and expanding new products and applications in nerve repair. I will now comment on our progress over the quarter in each of these areas.

First, we have continued to build market awareness of AxoGen and our products by engaging with surgeons at hospitals, clinical conferences and promotional events. We developed strong relationships with many well-known surgeons who are innovators and early adopters of our products.

They have been extremely helpful sharing our experiences, using our products with the clinical community and publishing the outcomes they have achieved around nerve injuries and repair solutions. We have also added Dr. Ivan Ducic to our team as Medical Director. Dr. Ducic is a renowned neurosurgeon and very respected in the nerve repair community.

He regularly engages with his peers and younger surgeons in the developing specialty of nerve repair, publishes his clinical findings and shares the clinical benefits associated with using the AxoGen product portfolio as one of the faculty of our surgeon education events.

We are also pleased with the increasing presence of nerve repair topics within the professional society meetings and conferences. We believe this is an indication of a broader surgeon awareness regarding the importance of peripheral nerve injuries and repair.

Just last month, at the combined meeting of the American Association for Hand Surgery, American Society for Peripheral Nerves and the American Society for Reconstructive Microsurgery, AxoGen hosted an educational symposium, the evolving algorithm in nerve repair and interactive case-based exercise with the experts.

This symposium focused on current concepts in peripheral nerve repair followed by a hands-on experience with AxoGen’s innovative products. A panel of experts discussed recent updates to peer review literature and how their nerve repair algorithm is evolving through the introduction of new technologies.

The interactive session was very well received with more than 100 surgeons in attendance. There was also great interest in our product portfolio with many visitors to our booth asking for more information. Our second pillar of growth is focused on surgeon education and the development of surgeon advocates.

We conducted a total of four national education events in the fourth quarter and a total of 13 national education events for the year. These courses are surgeon led and focused on the review of clinical data and emerging best practices in nerve repair, including these of AxoGen products.

These courses allow surgeons to gain additional confidence in nerve repair best practices and they drive adoption and increased utilization of our portfolio of products.

In fact this increased utilization is driving average annualized revenue and accounts for surgeons have completed these courses to increase over 100% six months following the completion of the course.

Because of the positive surgeon response of these courses, we will continue to expand our educational efforts and expect to complete 15 national courses during 2017. We will also continue to host educational symposia at professional conferences as well as smaller regional events throughout the year.

Our third pillar is to grow the body of clinical evidence. Our sponsored clinical projects Recon and Ranger are active and enrolling.

Recon, our Phase 3 pivotal study comparing Avance Nerve Graft to manufacture conduits in digital nerve injuries continues to enroll and is the long-term study to support the transition of Avance Nerve Graft to a biologic.

Our sponsored Ranger study is the largest multi-center registry in peripheral nerve repair with over a 1,000 Avance Nerve repairs enrolled to-date. We have supplemented this study with our MATCH study, which provides contemporary controls of allografts and manufactured conduits.

At the Sixth Annual Mayo Chang Gung Microsurgery Conference in October an update the MATCH cohort was presented.

The investigators reported that Avance Nerve Graft with a meaningful recovery rate of 85% provided a statistically significant difference with regard to return of sensory function as compared to manufactured conduits, which only provided a 51% level of meaningful recovery.

This data reinforces what was observed in our change studies that we published last year. The MATCH study continues to enroll and we look forward to sharing additional data from both the conduit and allograft arms as they become available.

The study continued to produce important data that assist in clinical decision making and support the adoption of our surgical portfolio. In addition to the adoption we are experiencing with hand and plastic surgeons, we continued to see our portfolio expand in oral and maxillofacial surgeries.

As surgeons become comfortable with AxoGen’s portfolio and digital trigeminal nerve injuries, they began to apply these technologies to more complex injuries such as benign tumor reconstructions in the head and neck.

Surgeons now have an option to reconstruct these nerves giving patients the opportunities return to function and avoid the social stigma associated with numbness of the lip, mouth and chin.

At the American Association of Oral and Maxillofacial Surgeons Meeting in September, two separate clinical presentations focusing on long segmental nerve repair due to benign tumor reconstructions were included.

These investigator initiative studies show promising results for the large gap defects of up to 70 millimeter and consistent results with our previously reported Ranger study. Long gap procedures like this were either previously not feasible or not viable.

Now they are becoming potential treatment options for these patients and we are pleased to see our technologies play a role in these surgeries. It is truly a privilege to be able to offer surgeon technologies that can help restore function and quality of life to these patients.

In 2016, there were 21 separate presentations of data on AxoGen surgical products, 12 of which were studies from independent investigators. The increasing number of penetrations featuring AxoGen products indicates the growing enthusiasm among surgeons for our products.

We now have a total of 44 separate peer review publications which continues to reinforce both the importance of peripheral nerve repairs and the growing body of evidence for AxoGen’s products in nerve repair. Our fourth pillar is sales execution, our growing sales organization is solidly executing on driving strong revenue growth.

We had 452 active accounts in the fourth quarter which is up 41% compared to a year ago. We ended the year with 51 direct sales reps, of which 34 have now been with us for at least 12 months. In addition to our direct sales force, we have 20 independent distribution partners supporting the execution of our sales strategy.

In the fourth quarter we added a net seven direct sales reps and for the year we added total of a net ten. Additionally in Q4, we also expanded our sales leadership team to accommodate our current and expected growth.

We expect to continue to add five to ten sales reps per year just as we have done over the last few years with most of that additional growth to occur in the second half of 2017. Our fifth pillar of growth is the introduction of new products and applications in nerve repair.

AxoGen believes there are many additional unmet needs in the surgical repair pro forma and we as the leading company in this space are positioned to develop new solutions for these needs. Avive Soft Tissue Membrane is an example of our deep understanding of nerves and nerve repair.

Chronic inflammation can impair tissue regeneration and result in scarring and fibrosis that in turn can irritate and compress the nerve. Trauma and surgical interventions can trigger the body’s repairs response which can result in inflammation in the surgical arena. When this occurs it can compromise the surgical outcomes of nerve repair.

Our research led us to the study of amniotic membranes as a potential biomaterial for this application. In utero amniotic membrane service a selected barrier, separating the tissue layers of the mother and developing child. The material modulates the exchange of fluids and nutrients and service as a barrier to maternal inflammatory responses.

Amniotic membranes have been used for decades as a palpable wound dressing to help produce the risk of chronic inflammation and provide a protective covering to the area. Historically these materials have been chosen and friable for surgical applications. The materials lack the mechanical robustness to handle manipulation and suturing.

Additionally materials have short absorption times with wound guidelines actually recommending reapplication every few days. These properties limited the clinically utility of amniotic membranes for surgical implant applications.

To overcome these limitations we identified the properties of the amniotic layer of the umbilical cord as the robust source of human amniotic membrane. Like placental amnion, this material has beneficial properties of amnion.

However unlike placental amnion, it has the longer resorption time and is the mechanically robust biomaterial making it easy to handle suture or secure during a surgical procedure. In November we recorded the first clinical implant and commercial launch of our Avive Soft Tissue Membrane.

Avive Soft Tissue Membrane is a minimally processed human umbilical cord membrane that might be used as a resorbable soft tissue covering to separate tissue layers and modulate inflammation in the surgical bed.

Up to 8x thicker than traditional amnion after implant, Avive Soft Tissue Membrane stays in place for at least 16 weeks, providing a soft tissue covering to modulate information during the critical phases of tissue repair.

Earlier in the year we launched AcroVal Neurosensory & Motor Testing System, a nerve function evaluation system is designed to be used as a tool for surgeons and other allied health professionals in the measurement mapping and monitoring of patients with peripheral nerve injuries and conditions.

AcroVal consists of three different accessory devices designed to evaluate nerve sensory function and hand strength. The devices are intended to be used on a normal and intact skin and support to standardized evaluation and measurement of nerve function to improve patient peripheral nerve outcomes.

These new products continue to strengthen and differentiate our position in providing personal solutions and tools. Although our existing products in the upper extremity and oral and maxillofacial markets are prime revenue sources today.

Expansion opportunities in nerve repair and breast reconstruction, lower extremity surgery, head and neck surgery, urology and the surgical intervention for pain offer accident new and expanded revenue opportunities in the future.

We prioritize two specific areas where the accident portfolio of products could bring meaningful solutions to current clinical challenges. Breast reconstruction neurotization and the repair of iatrogenic injuries associated with lower limb total joint replacements.

We began market development activities in these applications in Q4 with an expectation that we will launch with one of these new applications late this year. Breast reconstruction neurotization provides an exciting opportunity for women following a mastectomy.

Today, when women undergo breast reconstruction they get the shape of a breast, but they typically forfeit sensory function. This loss can cause women to feel abnormal, which is exactly the opposite of why they underwent breast reconstruction in the first place. They wanted to feel normal again.

We conducted a breast reconstruction neurotization meeting in November with a group of key opinion leading surgeons. We discussed the challenges and concerns women face following mastectomy and reviewed clinical techniques that may allow the return of breast in patients for a woman who choose reconstruction.

The group was enthusiastic about the potential of neurotizing the breast. In fact, one of the attending surgeons commented, if possible, all autologous flaps can and should be neurotized every patient as the candidate.

We will continue to meet with plastic surgeons to discuss this exciting new application for our nerve repair products and evaluate the market opportunity. We are also assessing the repair of iatrogenic injuries that involve damage to nerves as a result of total joint replacements.

In accessing the joint, the orthopedic surgeon has to transect a number of nerves. Periodically, these transected nerves form a painful tangle of nerve fibers called the neuroma. Unfortunately, the patient had surgery because of painful joints and now they may have pain again.

Recent clinical data has shown that with proper patient selection, a nerve surgeon can cut out the painful neuroma to reduce the pain and repair the resulting gap in the nerve to restore functions. Our current customer base of hand and plastic surgeons are equipped to address these injuries in ways that orthopedic surgeons are not.

We believe that we have the opportunity to develop peripheral patterns and awareness that bring these patients to our current customers. We intend to fully understand these markets and potentially create additional revenue opportunities for 2018 and beyond.

Before I turn the call over to Pete, I want to note that 2016 was a great year for us not only in terms of commercial execution, but also in our efforts to advance our strategic initiatives. In 2016, we grew revenue by 50% to $41.1 million and increased our gross margins to 84.3%.

We improved our EBITDA loss and reduced our operating cash burn and made important additions to our leadership team and our Board of Directors.

We improved our clinical and commercial execution with our current products and in our current markets, while also launching two new innovative products, expanding the basic clinical evidence supporting our nerve repair solutions, supporting educational programs for surgeons and fellows and increasing awareness of peripheral nerve injury and repair.

And our recent equity raise and the debt refinancing provided us with a solid capital structure to continue to drive growth and awareness in this emerging peripheral nerve market. We began 2017 with a track record of successful execution, strengthened clinical and commercial teams and a solid capital structure.

Surgeons are demonstrating an increasing awareness in adoption of the AxoGen portfolio of products in our current applications and we are making investments towards important expansion markets in breast reconstruction and neurotization and the repair of iatrogenic orthopedic nerve injuries.

We are pleased with our progress and with the opportunity to continue to develop the emerging nerve repair market and drive long-term sustainable growth. Now, I will turn the call over to Pete.

Pete?.

Thanks, Karen. Fourth quarter revenue was $11.4 million, a 46% increase over the prior year. The growth in revenue was primarily the result of the increases in unit volume as well as the net impact of price increases and changes in product mix. As in prior quarters, the majority of our revenue growth is driven by growth in active accounts.

Additionally, we continue to see growth in our pipeline of new accounts as surgeons become familiar with our products and begin to expand their treatment algorithms. Gross profit for the fourth quarter was $9.6 million, an increase of 50% compared to the prior year’s fourth quarter.

Gross margin for the fourth quarter was 84% compared to 81.9% in the prior year. The year-over-year increase was driven by growth in unit volume, operational efficiencies and the net impact of price increases and changes in product mix. Total operating expenses in the fourth quarter were $12.3 million, up 36% over prior year.

This increase was due to additional surgeon education programs, increased investment in market development and awareness activities, cost associated with the launch of Avive Soft Tissue Membrane, and expansion of our sales team and leadership structure.

These investments are driving growth in the company’s operating expenses, but importantly at a lower rate than sales growth, demonstrating the continued operating leverage of our business model. Sales and marketing expenses in the fourth quarter were $8.3 million up 43% over prior year.

As a percentage of revenue, sales and marketing expenses improved to 73% compared to 75% in the prior year fourth quarter. And as Karen mentioned, we ended the quarter with 51 direct sales reps, up from 41 at the end of 2015. However, 7 of the 10 net sales rep additions during the fourth quarter – occurred in the fourth quarter of ‘16.

We also added to our sales leadership structure in the fourth quarter to accommodate both our current and anticipated growth. Additionally, we completed 13 national education courses in the calendar year, 4 of these events occurred in the fourth quarter. And we anticipate conducting 15 of these events in 2017.

R&D spending in the fourth quarter was $1.2 million compared to $894,000 in the prior year’s fourth quarter.

Research and development costs included product development, including final development cost of the Avive Soft Tissue Membrane as well as expenditures in our clinical efforts with the RANGER Registry, the RECON study and support of our biologic license application for the advanced nerve graft as well as support of additional clinical research activity.

As a percentage of revenue, R&D expenses for Q4 of ‘16 were 10.3% compared to 11.4% in the prior year’s fourth quarter. In the fourth quarter, general and administrative expenses were $2.8 million, up 20% over the prior year.

As a percentage of revenue, general and administrative expenses improved to 24% compared to 30% in the prior year’s fourth quarter. In total, SG&A expenses as a percentage of revenue improved to 97% in Q4 compared to a 105% in the prior year.

EBITDA loss in the quarter was $2.6 million compared to an EBITDA loss of $2.6 million in the prior year’s fourth quarter. Net loss in the fourth quarter was $5.6 million or $0.17 per share and included $2.3 million or $0.07 per share related to the net charges associated with the refinancing of our debt.

Excluding these charges, adjusted net loss improved to $3.4 million or $0.10 per share in the fourth quarter of ‘16 compared to a net loss of $3.6 million or $0.12 per share in the fourth quarter of ‘15. Cash increased $14 million in the quarter to $30 million compared to $60 million at the end of the third quarter.

The net increase was due to $18.6 million of net proceeds received in the October equity raise partially offset by $2.9 million of prepayment and other fees paid in the quarter related to the October debt refinancing. After these items, the net operating use of cash in Q4 was $1.7 million.

As we have previously disclosed, we closed on a new debt, a new lower cost debt facility with mid cap financial in October. We used the proceeds of this facility to repay and retire our previous $25 million debt facility.

The new agreement provides for up to $31 million of debt comprised of a $21 million term loan and a revolving line of credit of up to $10 million. The revolver maybe increased at a later date to $15 million at our request and with the approval of mid capital.

However, the amount available under our revolver subject to our borrowing base, which is tied to certain accounts receivable in inventory balances. At December 31, our borrowing base was $5.5 million and we have $4 million borrowed on the revolver.

The facility carries a 54-month term with interest-only payments on the term loan for the first 24 months. In Q4, the interest rate our mid cap term loan was 8.5% and the interest rate on the revolving line of credit was 5%.

Total bank debt outstanding at the end of 2016 inclusive of both the term loan and the revolver and excluding the impact of deferred financing fees was $25 million, which is flat with the balance of total bank debt at the end of the third quarter.

Total interest and other expenses in Q4 amounted to $2.9 million and included net prepayment and related refinancing charges of approximately $2.3 million.

This net charge was comprised of a prepayment fees bode on the exit of the previous facility of $2.3 million which was partially offset by approximately $750,000 of deferred interest charges on the previous facility, plus the write-off of deferred financing fees on the previous facility which also approximated to $750,000.

Interest expense in the quarter excluding the impact of this net charge was approximately $600,000. Annual interest costs savings of this new facility will be at least $1.5 million compared to the previous debt facility.

Additionally, fees and expenses associated with this agreement were approximately $800,000, which were capitalized as deferred financing fees, approximately $658,000 of these fees were paid in Q4.

Today’s press release also notes that this is the first year that we are required to fully implement the internal control testing and audit provisions of Sarbanes Oxley section 404.

Our assessment of internal control structure as of December 31, 2016 revealed material weaknesses related to the design and operation of key controls around the calculations of significant judgment and estimates as well as quarterly cycle count procedures associated with consigned inventories.

Our assessment has not resulted in any changes of prior period financial results or statements. And subsequent to year end, we reviewed and modified the design of internal controls over these areas and we will continue to make additional modifications as necessary.

The material weaknesses will not be considered re-mediated until the applicable remedial controls operate for a sufficient period of time and we have concluded through testing that these controls are operating effectively.

Now as Karen mentioned we are pleased with the commercial clinical and strategic execution in 2016 from a financial perspective, we reported 2016 revenue of $41.1 million representing an increase of 50% over 2015.

Our gross margin is expanded and continued to be above 80% and we demonstrated the continued leverage of our business model by improving our EBITDA loss to $7.7 million in 2016 from $9 million in 2015. And we have positioned ourselves to continue to drive this growth in 2017.

Specifically in Q4, we made additional strategic investments in sales reps and leadership structure, surgeon education and new market development.

We launched the Avive Soft Tissue Membrane and saw the reporting of additional positive clinical data from our MATCH study comparing our Avance Nerve Grafts to conduits and additional data around successful outcomes in our expanding OMF opportunity.

We will continue to make investments to drive growth and we will do so in a manner that demonstrates the annual efficiency of our business model with improved margins and cash burn as revenue increases.

Our equity raise and refinanced lower cost debt provides us with the strengthened balance sheet to support our growth in this emerging peripheral nerve repair market and achieve profitability. Finally, we are regenerating our 2017 full year guidance.

We expect 2017 revenue will be at least 40% over 2016 revenues and gross margins will continue to be above 80%. And with that, I would like to hand the call back over to Karen..

Thanks Steve. Before we close, I would like to highlight a few investor events in the coming months that we will be participating in.

The BTIG Annual Medical Technology, Diagnostics and Healthcare IT Conference in Snowbird, Utah, March 1 and 2, the 29th Annual ROTH Conference in Dana Point, California on March 13, the Canaccord Genuity Musculoskeletal Conference in San Diego, California on March 14 and the Oppenheimer 27th Annual Healthcare Conference in New York City on March 21.

Information about these events will be available on the AxoGen website. In closing, our efforts to execute against our strategic initiatives focused on building market awareness, educating surgeons and developing advocates, growing the body of clinical evidence, executing on our sales plan and expanding new products and applications in nerve repair.

And these have resulted in record revenues and have positioned AxoGen to continue to lead and grow the emerging peripheral nerve repair market. We are building awareness and expanding usage of our products with innovator and early adopter surgeons and are excited to be moving towards developing the middle adopter segment of the nerve repair market.

We are introducing our products portfolio to fellows allowing us to train the next generation of nerve repair surgeons. And we will continue to expand our portfolio of products and develop new nerve repair applications where we believe we can bring meaningful solutions to current clinical challenges.

Before taking questions, I want to welcome our new investors and thank all of the members of the accident team for their commitment to helping patients with nerve injuries. At this point I would like to open up the line for questions.

Operator?.

At this time we will be conducting a question-and-answer session. [Operator Instructions] Our first question comes from the line of Dave Turkaly of JMP Securities. Please proceed with your question..

Thanks and just a firm one just a point of clarification, the guidance for ‘17, the 40% growth I was just curious, are you including any contribution from the new products.

And as a quick follow-up on that if we are looking at sort of $16 million in incremental sales, I was wondering if you might provide any color on sort of the breakout between AxoGuard and Avance, the mix there and do we expect potentially AxoGuard continues to maybe become more of your mix to grow a little faster in 2017?.

So first on the new products on – if you remember on AcroVal, we have said that AcroVal will always have modest revenue, it has no disposable component, it’s a capital project, it’s important part for our overall treatment algorithm and that it provides surgeons a way to measure their outcomes, but the revenue is not material, it is included in the guidance, but it’s not material.

Avive, we believe is a great and important part of our overall portfolio, but we think surgeons will adopt in the same way they have adopted nerve repair products in the past which means that they will try a few products and then they will wait and see outcomes.

And so we did not included in our thinking about the 40% growth, but we also believe it will be small this year. This year we are building a base that it really start to move into its rightful place next year. So well, it’s not included and it’s also not material in terms of the amount of revenue that it will provide in that first year.

So we think it will continue obviously to grow. In terms of your question about mix, historically we have seen that our revenue for Avance has been a little more than a half of our revenue in total. We haven’t given any kind of breakdown in terms of forward booking projections, but that’s actually been consistent over the last several years.

So historically you can see what our mix has been. [Technical Difficulty] And so Avive is really an ideal material to use in that type of application where the surgeon is wanting to separate tissue layers and again modulate inflammation..

Thanks a lot..

Our next question comes from the line of Tao Levy of Wedbush Securities. Please proceed with your question..

Great. Thanks. Good afternoon..

Thank you..

Hello..

I think you haven’t provided this type of guidance in the past, but given that you are breaking out your active accounts, should we assume that that number roughly increases by 40% next year as well kind of in line with your revenue growth?.

So we believe that our revenue growth will continue be a combination of driving penetration in existing active accounts as well as adding new active accounts. Actually I think our primary driver will be driving penetration that’s the bigger piece.

New active accounts come in a much smaller revenue dollar than obviously the opportunity exists to drive penetration. And so as we go forward in the next year, well, I think we would grow, certainly we will be adding new active accounts, it may not be at the same rate and I would not think that be detrimental to our revenue growth..

Got it.

And just maybe for clarification and so when you look at your 452 number of active accounts and you mentioned is around 5,100 centers out there, so it’s a little less than 10%, that doesn’t obviously mean that you are 10% penetrated in your opportunity, right, I mean that’s you are significantly lower than that within each of your active accounts, is that the right way?.

Actually, it’s true and in fact in our active accounts the level of penetration is usually very light. Our threshold for calling something an active account is just that they have got a very basic reorder patterns that are doing at least six orders in the last 12 months. And at that level, it’s a tinny single-digits penetrated in most cases.

So we have got a lot of room for upside growth and that’s actually why I think that our biggest opportunity is driving penetration in the active accounts, because we are such an entry level penetration in the accounts that we are in..

Got it, okay.

And just lastly maybe for Pete, should we expect higher G&A expenses this coming year related to the either having to fix the internals accounting controls or is that not a meaningful expense this year?.

Fixing the internal controls won’t drive additional significant G&A expense now. I think we have made some additions in the G&A line. We will continue to see some growth as necessary as we continue to grow, but not due to the controls this year..

Okay, great. Thank you very much..

Thank you..

Our next question comes from the line Bruce Jackson of Lake Street Capital Markets. Please proceed with your question..

Hi, nice quarter.

If I could challenge the remediation for the material deficiency, the way these things usually work [indiscernible] a year later when your auditors come in and then you get the final green light there everything is okay, so can you just tell us the process for fixing everything, you have made provisions to the procedures and then you are going to see how they are work and then should we just assume that the final audit takes place about a year from now, is that the way to think about it?.

Yes, that’s exactly right, Bruce. I mean, the Sarbanes Oxley test is an annual test with our auditors. We have certainly made modifications already. We will continue to – and we have modified controls and we have modified procedures and we will continue to maintain that and we will test those ourselves, manage them well on a regular quarterly basis.

So we are going to have confidence in that a lot sooner than what will show up in a formal Sarbanes Oxley 404 certification..

Okay.

And then just a quick question on the sales hiring plans for 2017, do you still plan to make a few adds to the sales force and do you have a target?.

Yes. Absolutely, we still see room for expansion in adding territories as well as splitting territories as they start to get above theoretical a peak level which we have set as – at about $2 million or above number. So we still see room to add. This year, we think we will add five to ten additional direct sales associates.

The majority of those will probably be in the later half of the year, but we will add reps..

Okay, great, that’s it for me. Thank you..

There are no further questions at this time. I would now like to turn the call back over to the President and CEO, Ms. Karen Zaderej for closing remarks..

Thank you, Tim. And I want to thank everyone for joining us on today’s call. I look forward to seeing many of you in person at one of the upcoming investor events and we look forward to speaking with you during our Q1 conference call in May. Thank you..

This concludes today’s conference. Thank you for your participation. You may disconnect your lines at this time. Have a wonderful evening..